{
    "nctId": "NCT00527826",
    "officialTitle": "A 12 Month Open-label Randomized Parallel Group Study to Investigate the Influence of Salmeterol Xinafoate/Fluticasone Propionate Either in Fixed Combination or Separately Via Diskus Inhalers on the Course of the Disease and Frequency of Exacerbations in Subjects With Severe and Very Severe COPD.",
    "inclusionCriteria": "* Subject must have a diagnosis of COPD based on the American Thoracic Society (ATS)/ European Respiratory Society (ERS) criteria.\n* Male or female subjects, aged \\>=40 years. Females must be of Non Child Bearing Potential. The definition of Non Child Bearing Potential is as following: Females, regardless of their age, with functioning ovaries and who have a current documented tubal ligation or hysterectomy, or females who are post-menopausal.\n* Have diagnosed COPD stage III or IV according to GOLD criteria: a baseline post-bronchodilator Forced Expiratory Volume, measured at 1 second (FEV1) \\<50% of predicted normal and a baseline post- bronchodilator FEV1/Inspiratory Vital Capacity (IVC) ratio \\<70%.\n* Have experienced at least 2 moderate or severe COPD exacerbations leading to medical consultation (requiring oral corticosteroids or increasing dosage of oral corticosteroids and/or antibiotics or hospitalization) within the 12 months preceding Visit 1.\n* Have stable COPD medication within 4 weeks prior to Visit 1 (no new medication added and no dosage changes in medication).\n* Current or ex-smokers with a smoking history of at least 10 pack years (number of pack years = \\[number of cigarettes per day / 20\\] x number of years smoked, e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years).\n* Are currently managed at home (outpatients), are ambulatory and able to travel to the clinic. Subjects can be treated with all relevant COPD medication. This includes vaccines, inhaled short-acting beta-2-agonists as needed, short-acting or long-acting anticholinergics (tiotropium), systemic beta-2-agonists, theophylline, mucolytics, antioxidants, beta-1-agonists (for cardiovascular indication), non-invasive ventilation, long term oxygen therapy and can have Cor Pulmonale.\n* A signed and dated written informed consent is obtained prior to participation.\n* Able to comply with the requirements of the protocol and be available for study visits over 52 weeks.\n* Must have minimum age of 40 Years",
    "exclusionCriteria": "* Known other respiratory disorders or signs for other respiratory disorders (e.g. asthma, lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis, bronchoectasis).\n* Known history of significant inflammatory disease, other than COPD (e.g. rheumatoid arthritis and systemic lupus erythematosus).\n* Known to be severely alpha-1-antitrypsin deficient (PI SZ or ZZ)\n* Having undergone lung surgery (e.g. lung resection including lung volume reduction surgery, lung transplant) or subjects scheduled for surgery.\n* Concurrent medication from Visit 1 and for the duration of the study with any of the prohibited medications: monoamine oxidase inhibitors and tricyclic antidepressants, and ritonavir (a highly potent cytochrome P450 3A4 inhibitor).\n* Subjects receiving chronic or prophylactic antibiotic therapy.\n* Serious, uncontrolled disease (including serious psychological disorders) likely to interfere with the study or impact on subject safety.\n* Have, in the opinion of the investigator, evidence of alcohol, drug or solvent abuse.\n* History of depression.\n* History or presence of clinically significant drug sensitivity or clinically significant allergic reaction to corticosteroids or salmeterol.\n* Moderate or severe COPD exacerbation (requiring corticosteroids or increased dosage of corticosteroids and/or antibiotics or hospitalization) within the 4 weeks prior to Visit 1\n* Lower respiratory tract infection within the 4 weeks prior to Visit 1 .\n* Pregnant or lactating female and female of childbearing potential.\n* Subject is a participating investigator, sub-investigator, study coordinator, or other employee of a participating investigator, or is an immediate family member of the before mentioned. Subject is an employee of GlaxoSmithKline (GSK).\n* Subject participated in an investigational drug study within 30 days prior to Visit 1"
}